Uptravi generic availability or uptravi patent expiration or selexipag generic?

Short answer:
- There is no FDA-approved generic Uptravi (selexipag) in the U.S. as of 2024.
- Uptravi remains a brand-name product; generic selexipag is not currently available in the U.S. or many other major markets.
- Patent protection for selexipag/use of selexipag is held by the rights holders, and the exact expiration depends on the specific patent family, country, term adjustments, and any pediatric or regulatory exclusivities. After all relevant patents and exclusivities expire in a given market, a generic version could enter, provided there are no other blocking patents or exclusivities.

What this means in plain language:
- If you’re in the U.S., as of now there isn’t a generic selexipag product on the market.
- In other countries, the situation is similar but can vary by patent status and regulatory decisions.
- The timeline for any potential generic depends on patent expiries and any extensions, which differ by country.

How to check the latest status (recommended):
- U.S. FDA Orange Book: search for Uptravi or selexipag to see listed patents and any exclusivities.
- U.S. patent status: USPTO Patent Center or Google Patents (look up “selexipag” to see active patent families and expiry dates).
- European status: European Patent Register or Espacenet for selexipag patents and expiry in EU member states.
- Company updates: Janssen/J&J press releases or regulatory filings may note patent status or generic challenges.

If you tell me your country (and whether you want the latest date-stamped patent numbers or just a general status), I can help outline the specific patent families and where to look for the exact expiration dates.